{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:37:45Z","timestamp":1791380265893,"version":"4.3.3"},"reference-count":50,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Viruses"],"abstract":"<jats:p>Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne bunyavirus with a mortality rate of up to 30%. There is no specific treatment for SFTSV. This article systematically reviews the progress of major anti-SFTSV drugs. The nucleotide analogues (favipiravir, 4\u2032-fluorouridine diphosphate prodrug VV261) have shown clinical potential. Calcium channel blockers (nifedipine, etc.) block virus invasion by inhibiting calcium influx. Monoclonal antibody (S2A5\/SNB02) has achieved targeted therapy, and SNB02 nanoantibody has entered clinical trials. However, many candidate agents predominantly focus on a single target, such as viral RdRp or host calcium channels, which makes it difficult to block the entire viral replication cycle and may accelerate the accumulation of resistant mutations. In addition, the low bioavailability of small-molecule drugs, the obstacles to industrial-scale production of antibody-based therapies, and the lack of Phase III clinical evidence severely restrict their clinical translation. Future research should focus on exploring viral replication mechanisms, developing drugs against key viral proteins, and designing multi-target combination therapies and novel drug delivery systems.<\/jats:p>","DOI":"10.3390\/v17091174","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:29:18Z","timestamp":1756376958000},"page":"1174","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent Advances in Therapeutics for Severe Fever with Thrombocytopenia Syndrome Virus"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0489-2607","authenticated-orcid":false,"given":"Huimin","family":"Dang","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Xu","sequence":"additional","affiliation":[{"name":"Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8503-8045","authenticated-orcid":false,"given":"Yigang","family":"Tong","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"},{"name":"Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Liang, S., Xie, W., Li, Z., Zhang, N., Wang, X., Qin, Y., Bao, C., and Hu, J. (2023). Analysis of Fatal Cases of Severe Fever with Thrombocytopenia Syndrome in Jiangsu Province, China, between 2011 and 2022: A Retrospective Study. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1076226"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00705-020-04731-2","article-title":"2020 Taxonomic Update for Phylum Negarnaviricota (Riboviria: Orthornavirae), Including the Large Orders Bunyavirales and Mononegavirales","volume":"165","author":"Kuhn","year":"2020","journal-title":"Arch. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Sun, J., Min, Y.-Q., Li, Y., Sun, X., Deng, F., Wang, H., and Ning, Y.-J. (2022). Animal Model of Severe Fever With Thrombocytopenia Syndrome Virus Infection. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.797189"},{"key":"ref_5","first-page":"629","article-title":"Survey and genetic analysis of severe fever with thrombocytopenia syndrome virus from Haemaphysalis longicornis","volume":"9","author":"Wang","year":"2014","journal-title":"J. Pathog. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633.e1","DOI":"10.1016\/j.cmi.2019.01.006","article-title":"Nosocomial Person-to-Person Transmission of Severe Fever with Thrombocytopenia Syndrome","volume":"25","author":"Jung","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_7","first-page":"209","article-title":"Hemorrhagic fever caused by a novel tick-borne Bunyavirus in Huaiyangshan, China","volume":"32","author":"Zhang","year":"2011","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3201\/eid2505.181463","article-title":"Endemic Severe Fever with Thrombocytopenia Syndrome, Vietnam","volume":"25","author":"Tran","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3346\/jkms.2013.28.6.795","article-title":"Severe Fever with Thrombocytopenia Syndrome: Tick-Mediated Viral Disease","volume":"28","author":"Chang","year":"2013","journal-title":"J. Korean Med. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/infdis\/jit603","article-title":"The First Identification and Retrospective Study of Severe Fever With Thrombocytopenia Syndrome in Japan","volume":"209","author":"Takahashi","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/rmv.1776","article-title":"Systematic Review of Severe Fever with Thrombocytopenia Syndrome:Virology, Epidemiology, and Clinical Characteristics","volume":"24","author":"Liu","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Seo, J.-W., Kim, D., Yun, N., and Kim, D.-M. (2021). Clinical Update of Severe Fever with Thrombocytopenia Syndrome. Viruses, 13.","DOI":"10.3390\/v13071213"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/978-1-4614-0980-9_11","article-title":"Bunyavirus: Structure and Replication","volume":"Volume 726","author":"Rossmann","year":"2012","journal-title":"Viral Molecular Machines"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1128\/JVI.02141-13","article-title":"Nonmuscle Myosin Heavy Chain IIA Is a Critical Factor Contributing to the Efficiency of Early Infection of Severe Fever with Thrombocytopenia Syndrome Virus","volume":"88","author":"Sun","year":"2014","journal-title":"J. Virol."},{"key":"ref_15","unstructured":"National Health Commission of the People\u2019s Republic of China, and National Administration of Traditional Chinese Medicine (2024). Diagnosis and treatment scheme for severe fever with thrombocytopenia syndrome (2023 Edition). Chin. J. Infect. Control., 23, 819\u2013929. (In Chinese)."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1002\/jmv.26544","article-title":"Severe Fever with Thrombocytopenia Syndrome in Hefei: Clinical Features, Risk Factors, and Ribavirin Therapeutic Efficacy","volume":"93","author":"Zhang","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Takayama-Ito, M., and Saijo, M. (2020). Antiviral Drugs Against Severe Fever With Thrombocytopenia Syndrome Virus Infection. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.00150"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/rmv.483","article-title":"Mechanisms of Action of Ribavirin against Distinct Viruses","volume":"16","author":"Graci","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.7883\/yoken.67.423","article-title":"Effects of Ribavirin on Severe Fever with Thrombocytopenia Syndrome Virus In Vitro","volume":"67","author":"Shimojima","year":"2014","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3904\/kjim.2016.109","article-title":"In Vitro Antiviral Activity of Ribavirin against Severe Fever with Thrombocytopenia Syndrome Virus","volume":"32","author":"Lee","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/cid\/cit530","article-title":"Case-Fatality Ratio and Effectiveness of Ribavirin Therapy Among Hospitalized Patients in China Who Had Severe Fever With Thrombocytopenia Syndrome","volume":"57","author":"Liu","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1473-3099(18)30293-7","article-title":"Epidemiological and Clinical Features of Laboratory-Diagnosed Severe Fever with Thrombocytopenia Syndrome in China, 2011\u20132017: A Prospective Observational Study","volume":"18","author":"Li","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a Potential Countermeasure against Neglected and Emerging RNA Viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an Anti-Influenza Drug against Life-Threatening RNA Virus Infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-021-00541-3","article-title":"Clinical Effect and Antiviral Mechanism of T-705 in Treating Severe Fever with Thrombocytopenia Syndrome","volume":"6","author":"Li","year":"2021","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1128\/AAC.00649-13","article-title":"Mechanism of Action of T-705 Ribosyl Triphosphate against Influenza Virus RNA Polymerase","volume":"57","author":"Sangawa","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00061-15","DOI":"10.1128\/mSphere.00061-15","article-title":"Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus","volume":"1","author":"Tani","year":"2016","journal-title":"mSphere"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/2040206617740303","article-title":"Establishment of an Antiviral Assay System and Identification of Severe Fever with Thrombocytopenia Syndrome Virus Inhibitors","volume":"25","author":"Baba","year":"2017","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Suemori, K., Saijo, M., Yamanaka, A., Himeji, D., Kawamura, M., Haku, T., Hidaka, M., Kamikokuryo, C., Kakihana, Y., and Azuma, T. (2021). A Multicenter Non-Randomized, Uncontrolled Single Arm Trial for Evaluation of the Efficacy and the Safety of the Treatment with Favipiravir for Patients with Severe Fever with Thrombocytopenia Syndrome. PLoS Negl. Trop. Dis., 15.","DOI":"10.1371\/journal.pntd.0009103"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Xu, H., Jian, X., Wen, Y., Xu, M., Jin, R., Wu, X., Zhou, F., Cao, J., Xiao, G., and Peng, K. (2024). A Nanoluciferase SFTSV for Rapid Screening Antivirals and Real-Time Visualization of Virus Infection in Mice. eBioMedicine, 99.","DOI":"10.1016\/j.ebiom.2023.104944"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1039\/D3OB00268C","article-title":"Synthesis and Evaluation of NHC Derivatives and 4\u2032-Fluorouridine Prodrugs","volume":"21","author":"Xiang","year":"2023","journal-title":"Org. Biomol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9811","DOI":"10.1021\/acs.jmedchem.5c00626","article-title":"Design and Development of a Novel Oral 4\u2032-Fluorouridine Double Prodrug VV261 against SFTSV","volume":"68","author":"Cheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41422-019-0214-z","article-title":"Calcium Channel Blockers Reduce Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Related Fatality","volume":"29","author":"Li","year":"2019","journal-title":"Cell Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e00015-23","DOI":"10.1128\/jvi.00015-23","article-title":"Calcium Influx Regulates the Replication of Several Negative-Strand RNA Viruses Including Severe Fever with Thrombocytopenia Syndrome Virus","volume":"97","author":"Urata","year":"2023","journal-title":"J. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S1995820X24001342","DOI":"10.1016\/j.virs.2024.08.007","article-title":"Antiviral Activity of Vitamin D Derivatives against Severe Fever with Thrombocytopenia Syndrome Virus in Vitro and in Vivo","volume":"39","author":"Luo","year":"2024","journal-title":"Virol. Sin."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jiac.2018.03.005","article-title":"Caffeic Acid, a Coffee-Related Organic Acid, Inhibits Infection by Severe Fever with Thrombocytopenia Syndrome Virus in Vitro","volume":"24","author":"Ogawa","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jiac.2020.10.015","article-title":"Structural Basis of Antiviral Activity of Caffeic Acid against Severe Fever with Thrombocytopenia Syndrome Virus","volume":"27","author":"Ogawa","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105479","DOI":"10.1016\/j.antiviral.2022.105479","article-title":"Amodiaquine Derivatives as Inhibitors of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Replication","volume":"210","author":"Baba","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1038\/s41467-024-51108-z","article-title":"A Broadly Protective Antibody Targeting Glycoprotein Gn Inhibits Severe Fever with Thrombocytopenia Syndrome Virus Infection","volume":"15","author":"Ren","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e136855","DOI":"10.1172\/jci.insight.136855","article-title":"A Single-Domain Antibody Inhibits SFTSV and Mitigates Virus-Induced Pathogenesis in Vivo","volume":"5","author":"Wu","year":"2020","journal-title":"JCI Insight"},{"key":"ref_41","unstructured":"Y-Clone Medical Science Co., Ltd. (2025, August 19). Technology Transfer and R&D Collaboration Agreement on SNB02\u00a0. Available online: www.y-clone.com."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.it.2015.01.004","article-title":"Interferons and Viruses: An Evolutionary Arms Race of Molecular Interactions","volume":"36","author":"Hoffmann","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: An Overview of Signals, Mechanisms and Functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ning, Y.-J., Mo, Q., Feng, K., Min, Y.-Q., Li, M., Hou, D., Peng, C., Zheng, X., Deng, F., and Hu, Z. (2019). Interferon-\u03b3-Directed Inhibition of a Novel High-Pathogenic Phlebovirus and Viral Antagonism of the Antiviral Signaling by Targeting STAT1. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01182"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.virs.2022.01.014","article-title":"Tilorone Confers Robust In Vitro and In Vivo Antiviral Effects against Severe Fever with Thrombocytopenia Syndrome Virus","volume":"37","author":"Yang","year":"2022","journal-title":"Virol. Sin."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"106141","DOI":"10.1016\/j.antiviral.2025.106141","article-title":"Kaempferide Enhances Type I Interferon Signaling as a Novel Broad-Spectrum Antiviral Agent","volume":"237","author":"Du","year":"2025","journal-title":"Antivir. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijid.2022.03.038","article-title":"Impact of Glycemia and Insulin Treatment in Fatal Outcome of Severe Fever with Thrombocytopenia Syndrome","volume":"119","author":"Ge","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e00634-25","DOI":"10.1128\/mbio.00634-25","article-title":"Metformin as Antiviral Therapy Protects Hyperglycemic and Diabetic Patients","volume":"16","author":"Wang","year":"2025","journal-title":"mBio"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"174178","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: Mechanism of Action, Challenges, and Therapeutic Approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Wang, X., Li, J., Li, J., Chen, Q., Zhang, Y., Chen, K., and Shang, S. (2025). Gn-Modified Biomimetic Nanospheres for Targeted siRNA Delivery and Their in Vitro Activity against Severe Fever with Thrombocytopenia Syndrome Virus. Int. J. Biol. Macromol., 309.","DOI":"10.1016\/j.ijbiomac.2025.142955"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1174\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T09:38:53Z","timestamp":1758879533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/9\/1174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["v17091174"],"URL":"https:\/\/doi.org\/10.3390\/v17091174","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}